Want to see AXSM full AI Analyst Report?
Total Valuation
Axsome Therapeutics has a market cap or net worth of $10.76B. The enterprise value is $12.58K.
Market Cap$10.76B
Enterprise Value$12.58K
Share Statistics
Axsome Therapeutics has 52,380,817 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,380,817
Owned by Insiders15.08%
Owned by Institutions19.28%
Financial Efficiency
Axsome Therapeutics’s return on equity (ROE) is -2.07 and return on invested capital (ROIC) is -43.95%.
Return on Equity (ROE)-2.07
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-43.95%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee474.37K
Profits Per Employee-136.09K
Employee Count1,346
Asset Turnover0.93
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Axsome Therapeutics is ―. Axsome Therapeutics’s PEG ratio is 1.29.
PE Ratio―
PS Ratio14.23
PB Ratio102.90
Price to Fair Value102.90
Price to FCF-96.78
Price to Operating Cash Flow-148.51
PEG Ratio1.29
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 638.50M and earned -183.17M in profits. Earnings per share was -3.68.
Revenue638.50M
Gross Profit591.02M
Operating Income-169.24M
Pretax Income-183.70M
Net Income-183.17M
EBITDA-168.08M
Earnings Per Share (EPS)-3.68
Cash Flow
In the last 12 months, operating cash flow was -71.26M and capital expenditures -129.00K, giving a free cash flow of -71.39M billion.
Operating Cash Flow-71.26M
Free Cash Flow-71.39M
Free Cash Flow per Share-1.36
Dividends & Yields
Axsome Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change69.61%
50-Day Moving Average230.44
200-Day Moving Average192.13
Relative Strength Index (RSI)35.67
Average Volume (3m)1.02M
Important Dates
Axsome Therapeutics upcoming earnings date is Nov 9, 2026, Before Open (Confirmed).
Last Earnings DateAug 10, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date―
Financial Position
Axsome Therapeutics as a current ratio of 1.55, with Debt / Equity ratio of 263.14%
Current Ratio1.55
Quick Ratio1.48
Debt to Market Cap0.02
Net Debt to EBITDA0.49
Interest Coverage Ratio-25.81
Taxes
In the past 12 months, Axsome Therapeutics has paid -530.00K in taxes.
Income Tax-530.00K
Effective Tax Rate<0.01
Enterprise Valuation
Axsome Therapeutics EV to EBITDA ratio is -53.57, with an EV/FCF ratio of -95.91.
EV to Sales14.10
EV to EBITDA-53.57
EV to Free Cash Flow-95.91
EV to Operating Cash Flow-96.40
Balance Sheet
Axsome Therapeutics has $319.85M in cash and marketable securities with $219.21M in debt, giving a net cash position of $100.64M billion.
Cash & Marketable Securities$319.85M
Total Debt$219.21M
Net Cash$100.64M
Net Cash Per Share$1.92
Tangible Book Value Per Share$0.72
Margins
Gross margin is 93.24%, with operating margin of -26.51%, and net profit margin of -28.69%.
Gross Margin93.24%
Operating Margin-26.51%
Pretax Margin-28.77%
Net Profit Margin-28.69%
EBITDA Margin-26.32%
EBIT Margin-27.74%
Analyst Forecast
The average price target for Axsome Therapeutics is $291.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$291.00
Price Target Upside20.75% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast56.87%
EPS Growth Forecast25.87%